Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology (ACR).  CCX354 is an orally-active small molecule that specifically targets and inhibits the chemokine receptor known as CCR1, which is implicated in the development and progression of rheumatoid arthritis (RA).  Results showed that CCX354 was safe and well tolerated by patients with RA in this clinical trial, and demonstrated clinical and biological activity at a dose of 200 mg once daily.  These data were highlighted today in a late-breaker oral presentation in Chicago entitled "Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase II Rheumatoid Arthritis Study".

"The initial cloning and characterization of CCR1 as well as the chemokine known as RANTES, one of the main ligands for CCR1, was accomplished by the founder of ChemoCentryx over twenty years ago," stated Paul-Peter Tak, M.D., Ph.D., Lead Investigator and Professor at AMC/University of Amsterdam, currently also Senior Vice President/Head, Therapy Area ImmunoInflammation at GlaxoSmithKline.  "Although there has been strong evidence implicating CCR1 in the pathology of RA, this is the first time that an investigational CCR1 antagonist has successfully demonstrated clinical efficacy in patients with this disease."

The results reported from this study, known as the CARAT-2 clinical trial, show that patients who met inclusion criteria at the start of dosing (Day 1 eligible) had an ACR20 response at Week 12 of 56% in patients receiving 200 mg CCX354 once daily compared to 44% in patients receiving 100 mg twice daily, and 30% in patients receiving placebo. The difference between 200 mg once daily and placebo was statistically significant (p=0.014). The decrease in CRP, a marker of inflammation, was statistically significant in the 200 mg QD group com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Persistence Market Research ... Market Study on Ophthalmic Devices: Asia ... devices market was valued at USD 29,171.5 million in 2014 ... 6.5% from 2014 to 2020, to reach an estimated ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... 22, 2014  For many people experiencing issues ... facing the prospect of large, painful incisions and ... activities are also impacted, such as working, driving ... the problem, some patients even delay necessary treatment, ... lead to permanent damage for some conditions. ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...
... open-label study presented ... at ... AMLN ) today announced data showing that the use of ... in more patients achieving diabetes treatment goals of,improved glucose control without ...
Cached Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5
(Date:9/22/2014)... 22, 2014 On Tuesday, September 16th, 2014, ... first evening show, “KC After Dark.” Hosted by top ... Dark” will air every Tuesday at 8:00 p.m. EST. WRNW1 ... the 50th caller, and because of the amazing turnout for ... in mark with 500 callers. , During this comical, ...
(Date:9/22/2014)... people both exercise more and drink more , Study ... activity , Findings differ from past research on physical ... Medicine study finds that on days when people exercise ... more alcohol, too. , This is the only study ... for self-reporting physical activity and alcohol use. , "Monday ...
(Date:9/22/2014)... 22, 2014 Transvaginal mesh lawsuits ... continue to move forward in the federal multidistrict ... District of West Virginia, Bernstein Liebhard LLP reports. ... Order was issued by the Court on September ... to the upcoming trial for consolidated lawsuits involving ...
(Date:9/22/2014)... Boston, MA Up to 40 percent of patients ... may fail to remove all the cancerous tissue in ... Hospital (BWH) have successfully tested a tool they developed ... from normal tissue, thereby decreasing the chances for repeat ... online the week of September 22, 2014 in the ...
(Date:9/22/2014)... An inventor and anesthesiologist applied what she learned ... "My lower arm always became numb when I slept ... this problem," she said. "It’s better to be able ... 'fall asleep.'" , The Sleeping Pillow enables a user ... It avoids pain and restlessness by reducing pressure on ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:We drink more alcohol on gym days 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2
... SAGE and the European Society of Cardiology (ESC) have ... Acute Cardiovascular Care. The first issue will be published ... over 70,000 cardiology professionals across Europe and the Mediterranean, ... publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- From buying a Christmas tree to stringing ... and safety issues parents and guardians should consider during the holidays, ... offers the following tips to help keep children and the whole ... sure, if you select an artificial tree, that it is flame-resistant. ...
... The busy holiday season may disrupt many people,s daily routines, ... to remember to look after your teeth, an expert advises. ... treats and drink alcoholic beverages more than usual," Dr. George ... an academy news release. "Additionally, with their busy schedules ...
... It,s not likely that a policy of presumed consent would ... according to a new study. Under such a ... organs after death unless they explicitly forbid it while they,re ... say it would help ease the organ shortage in the ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... News) -- ,Draft recommendations meant to increase the number ... released Friday by the U.S. Food and Drug Administration. ... factors, and types of illness may cause women to ... men, according to the FDA. But, women are ...
Cached Medicine News:Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Pediatricians Offer Tips to Avoid Holiday Hazards 2Health News:Pediatricians Offer Tips to Avoid Holiday Hazards 3Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Presumed Consent Wouldn't Boost U.S. Organ Donation: Study 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:FDA Seeks to Get More Women Into Trials of Medical Devices 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: